Abstract Details

Title Neural Correlates of the Improvement of Motor and Non-motor Symptoms in Parkinson’s Disease Following a Combined Digital and Levodopa Therapy

Topic Movement Disorders

Presentation(s) S11 - Movement Disorders: Technological Advances in Diagnostics and Therapeutics (3:54 PM-4:06 PM)

Poster/Presentation
Number 003

Objective We aimed to demonstrate the parallel neural mechanisms underlying the effects of combining standard levodopa treatment with the DopApp digital intervention on motor and non-motor symptoms in Parkinson’s disease (PD).

Background Despite the availability of pharmacological treatments, PD remains associated with significant unmet clinical needs, particularly in managing non-motor symptoms and underlying neural circuit dysfunction. Combining digital therapeutics with dopaminergic therapy may enhance clinical outcomes by promoting adaptive plasticity within affected brain networks.

Design/Methods Forty-two PD patients treated with levodopa participated in a prospective, double-blind, randomized, placebo-controlled trial. The 3-week digital treatment consisted of a proprietary daily protocol combining multisensory motor, psychological, and cognitive training. This included fine-motor exercises and rehabilitation-focused modules (physiotherapy, speech therapy, dance-based activities, etc.), along with sensory-depravation tasks and daily walking. Patients were assessed pre- and post-treatment using clinical and psychological scales and resting-state fMRI (rsFC) scans. App usage data were analyzed to derive engagement metrics.

Results DopApp treatment significantly improved the total MDS-UPDRS score compared to placebo-app (inter-group difference of 7.8 points, p=0.0005). Several exploratory endpoints were also statistically significant, including MDS-UPDRS II,III and Beck Depression Inventory (BDI-II) scores. These effects were associated with parallel modulation of rsFC within the thalamocortical motor and limbic networks. Moreover, increased engagement with sensorimotor and emotion regulation activities correlated with both enhanced clinical effects and rsFC alterations, suggesting a digital dose-response relationship and task-specific neural plasticity.

Conclusions This study provides preliminary clinical and neurobiological evidence that a targeted, digital therapeutic can augment standard dopaminergic treatment in PD. Dose-response relationships between engagement and outcomes suggest that adaptive, task-specific digital tools may drive circuit-selective plasticity. These findings support the integration of scalable digital interventions into precision drug-digital strategies for neurodegenerative disease treatment, representing an early step toward hybrid approaches that personalize care, enhance efficacy, and extend reach beyond traditional setting.

Authors/Disclosures
Shahar Shelly, MD (Rambam Medical Center) PRESENTER	Dr. Shelly has or had stock in Remepy.
Tal Tamir	Dr. Tamir has nothing to disclose.
Rotem Sivan Hoffmann, MD	Dr. Sivan Hoffmann has nothing to disclose.
Brett Colbert, MD, PhD	Dr. Colbert has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Remepy. Dr. Colbert has stock in Remepy.
Merav Catalogna, PhD	Dr. Catalogna has nothing to disclose.

��ɫ��

��ɫ��